Mineralys Therapeutics Inc
MLYS
NASDAQ
Biotechnology
$25.64
USD
-0.45 (-1.72%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.31B
Volume 697.7K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-349.58M
TTM
-83.2%
YoY
Operating Cash Flow
$-138.79M
TTM
+28.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 8.5 | 9.7 | 13.9 | 21.0 | 24.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 46.7 | 41.1 | 38.3 | 45.3 | 246.0 |
Operating Income | -46.7 | -41.1 | -38.3 | -45.3 | -246.0 |
EBITDA | -46.7 | -41.1 | -38.3 | -45.3 | -246.0 |
Other Income / Expense | -0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 3.5 | 4.2 | 6.0 | 6.0 | 5.0 |
Income Before Income Taxes | -43.3 | -36.9 | -32.2 | -39.3 | -241.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -43.3 | -36.9 | -32.2 | -39.3 | -241.1 |
Consolidated Net Income / Loss | -43.3 | -36.9 | -32.2 | -39.3 | -241.1 |
Net Income Attributable to Common Shareholders | -43.3 | -36.9 | -32.2 | -39.3 | -241.1 |
Basic EPS | -$0.66 | -$0.52 | -$0.40 | -$0.47 | -$2.85 |
Diluted EPS | -$0.66 | -$0.52 | -$0.40 | -$0.47 | -$2.85 |
Basic Shares Outstanding | 65.5M | 70.6M | 81.4M | 82.8M | 84.7M |
Diluted Shares Outstanding | 65.5M | 70.6M | 81.4M | 82.8M | 84.7M |